Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:1368-1377
© 1999 American Heart Association, Inc.
Brief Reviews |
Measuring Plasma Fibrinogen to Predict Stroke and Myocardial Infarction
An Update
From the Clinica Medica, Dipartimento di Medicina Clinica e Sperimentale (G.M.), Ateneo "Federico II" Napoli; Laboratoro di Epidemiologia Clinica Cardiovascolare, Istituto di Ricerche Farmacologiche Mario Negri (A.D.B., R.M.), Consorzio Mario Negri Sud, S. Maria Imbaro (CH); Istituto di Medicina Interna e Geriatria (G.D.M.), Università di Palermo, Italy.
Correspondence to Giovanni Di Minno, MD, Clinica Medica, Dipartimento di Medicina, Clinica e Sperimentale, Via S. Pansini 5, 80131 Napoli, Italy. E-mail diminno{at}unina.it
Abstract—Plasma fibrinogen is a major determinant of platelet aggregation and blood viscosity. The decrease in plasma fibrinogen by bezafibrate is associated with a decrease in the risk of reinfarctions. To strengthen the predictive value of plasma fibrinogen with respect to cardiovascular risk, we performed a meta-analysis of studies conducted between 1984 and 1998. Emphasis has been put on the relationship between high levels of plasma fibrinogen and fatal and/or nonfatal cardiovascular events in both the general population and in patients with previous cardiovascular events. Twenty-two studies (13 prospective, 5 cross-sectional, and 4 case-control) addressing the association between fibrinogen plasma concentrations and cardiovascular disease were analyzed. The overall estimate of risk of cardiovascular event in subjects with plasma fibrinogen levels in the higher tertile, was twice as high as that of subjects in the lower one (odds ratio, 1.99; 95% confidence interval, 1.85 to 2.13). High plasma fibrinogen levels were associated with an increased risk of cardiovascular disease in healthy as much as in high-risk individuals. A metaregression showed no confounding effects attributable to selected characteristics of retrieved studies. A subgroup analysis (study design, follow up, mean fibrinogen levels, percentage of smokers, and mean age) allowed us to conclude that fibrinogen is an independent risk factor for cardiovascular disease; that it interacts with major determinants of myocardial and cerebrovascular ischemia; and that, in secondary prevention studies, it enhances by 8% the prediction of future events by established risk factors. Thus, fibrinogen measurements should be encouraged to refine the overall risk profiles of individuals and to better tailor preventive interventions.
Key Words: fibrinogen • risk factor • stroke • myocardial ischemia • meta-analysis
This article has been cited by other articles:
 |
|
 |
|
  D. S. Frankel, J. B. Meigs, J. M. Massaro, P. W.F. Wilson, C. J. O'Donnell, R. B. D'Agostino, and G. H. Tofler Von Willebrand Factor, Type 2 Diabetes Mellitus, and Risk of Cardiovascular Disease: The Framingham Offspring Study Circulation, December 9, 2008; 118(24): 2533 - 2539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Koch, P. Hoppmann, J. Biele, J. C. Mueller, A. Schomig, and A. Kastrati Fibrinogen Genes and Myocardial Infarction: A Haplotype Analysis Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 758 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O Rogowski, I Shapira, A Shirom, S Melamed, S Toker, and S Berliner Heart rate and microinflammation in men: a relevant atherothrombotic link Heart, August 1, 2007; 93(8): 940 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Pilote, K. Dasgupta, V. Guru, K. H. Humphries, J. McGrath, C. Norris, D. Rabi, J. Tremblay, A. Alamian, T. Barnett, et al. A comprehensive view of sex-specific issues related to cardiovascular disease Can. Med. Assoc. J., March 13, 2007; 176(6): S1 - S44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Maxwell, E. Westein, W. S. Nesbitt, S. Giuliano, S. M. Dopheide, and S. P. Jackson Identification of a 2-stage platelet aggregation process mediating shear-dependent thrombus formation Blood, January 15, 2007; 109(2): 566 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Y.-P. Ho, M.-J. Chen, W. H.-H. Sheu, Y.-C. Yi, A. C.-W. Tsai, H.-F. Guu, and E. S.-C. Ho Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women Hum. Reprod., October 1, 2006; 21(10): 2715 - 2720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sato, H. Iso, H. Noda, A. Kitamura, H. Imano, M. Kiyama, T. Ohira, T. Okada, M. Yao, T. Tanigawa, et al. Plasma Fibrinogen Concentrations and Risk of Stroke and Its Subtypes Among Japanese Men and Women Stroke, October 1, 2006; 37(10): 2488 - 2492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. von Kanel, U. Hepp, C. Buddeberg, M. Keel, L. Mica, K. Aschbacher, and U. Schnyder Altered Blood Coagulation in Patients With Posttraumatic Stress Disorder Psychosom Med, July 1, 2006; 68(4): 598 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ziakas, S. Gavrilidis, G. Giannoglou, E. Souliou, K. Gemitzis, D. Kalampalika, M. A. Vayona, I. Pidonia, G. Parharidis, and G. Louridas In-Hospital and Long-Term Prognostic Value of Fibrinogen, CRP, and IL-6 Levels in Patients with Acute Myocardial Infarction Treated with Thrombolysis Angiology, May 1, 2006; 57(3): 283 - 293. [Abstract] [PDF]
|
|
|
|
 |
|
 A. A. Quyyumi Women and Ischemic Heart Disease: Pathophysiologic Implications From the Women's Ischemia Syndrome Evaluation (WISE) Study and Future Research Steps J. Am. Coll. Cardiol., February 7, 2006; 47(3_Suppl_S): S66 - S71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M C. S M Leao, M. P. C Duarte, D. M. B Silva, P. R. V Bahia, C. M. Coeli, and M. L. F. de Farias Influence of methyltestosterone postmenopausal therapy on plasma lipids, inflammatory factors, glucose metabolism and visceral fat: a randomized study Eur. J. Endocrinol., January 1, 2006; 154(1): 131 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Smith, C. Patterson, J. Yarnell, A. Rumley, Y. Ben-Shlomo, and G. Lowe Which Hemostatic Markers Add to the Predictive Value of Conventional Risk Factors for Coronary Heart Disease and Ischemic Stroke?: The Caerphilly Study Circulation, November 15, 2005; 112(20): 3080 - 3087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Fibrinogen Studies Collaboration* Plasma Fibrinogen Level and the Risk of Major Cardiovascular Diseases and Nonvascular Mortality: An Individual Participant Meta-analysis JAMA, October 12, 2005; 294(14): 1799 - 1809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Feinbloom and K. A. Bauer Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2043 - 2053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Smith, R. Harbord, J. Milton, S. Ebrahim, and J. A.C. Sterne Does Elevated Plasma Fibrinogen Increase the Risk of Coronary Heart Disease?: Evidence from a Meta-Analysis of Genetic Association Studies Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2228 - 2233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Woodward, G. D.O. Lowe, D. J. Campbell, S. Colman, A. Rumley, J. Chalmers, B. C. Neal, A. Patel, A. J. Jenkins, B. E. Kemp, et al. Associations of Inflammatory and Hemostatic Variables With the Risk of Recurrent Stroke Stroke, October 1, 2005; 36(10): 2143 - 2147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. I. Paraskevas, S. S. Daskalopoulou, M. E. Daskalopoulos, and C. D. Liapis Secondary Prevention of Ischemic Cerebrovascular Disease. What Is the Evidence? Angiology, September 1, 2005; 56(5): 539 - 552. [Abstract] [PDF]
|
|
|
|
|
|
H. J. Milionis, E. Rizos, J. Goudevenos, K. Seferiadis, D. P. Mikhailidis, and M. S. Elisaf Components of the Metabolic Syndrome and Risk for First-Ever Acute Ischemic Nonembolic Stroke in Elderly Subjects Stroke, July 1, 2005; 36(7): 1372 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Elosua, B. Bartali, J. M. Ordovas, A. M. Corsi, F. Lauretani, L. Ferrucci, and on Behalf of the InCHIANTI Investigators Association Between Physical Activity, Physical Performance, and Inflammatory Biomarkers in an Elderly Population: The InCHIANTI Study J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2005; 60(6): 760 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Soria, L. Almasy, J. C. Souto, A. Buil, M. Lathrop, J. Blangero, and J. Fontcuberta A Genome Search for Genetic Determinants That Influence Plasma Fibrinogen Levels Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): 1287 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Arikan and S. Sen Endothelial Damage and Hemostatic Markers in Patients with Uncomplicated Mild-to-Moderate Hypertension and Relationship with Risk Factors Clinical and Applied Thrombosis/Hemostasis, April 1, 2005; 11(2): 147 - 159. [Abstract] [PDF]
|
|
|
|
|
|
A M Smith, K M English, C J Malkin, R D Jones, T H Jones, and K S Channer Testosterone does not adversely affect fibrinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina Eur. J. Endocrinol., February 1, 2005; 152(2): 285 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. J. Kullo and C. M. Ballantyne Conditional Risk Factors for Atherosclerosis Mayo Clin. Proc., February 1, 2005; 80(2): 219 - 230. [Abstract] [PDF]
|
|
|
|
 |
|
 M P J van Goor, E B Gomez-Garcia, F W G Leebeek, G J Brouwers, P J Koudstaal, and D W J Dippel The - 148 C/T fibrinogen gene polymorphism and fibrinogen levels in ischaemic stroke: a case-control study J. Neurol. Neurosurg. Psychiatry, January 1, 2005; 76(1): 121 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Rothwell, S. C. Howard, D. A. Power, S. A. Gutnikov, A. Algra, J. van Gijn, T. G. Clark, M. F.G. Murphy, C. P. Warlow, and for the Cerebrovascular Cohort Studies Collaborati Fibrinogen Concentration and Risk of Ischemic Stroke and Acute Coronary Events in 5113 Patients With Transient Ischemic Attack and Minor Ischemic Stroke Stroke, October 1, 2004; 35(10): 2300 - 2305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F Viles-Gonzalez, V. Fuster, and J. J Badimon Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences Eur. Heart J., July 2, 2004; 25(14): 1197 - 1207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J Baer, J. T Judd, B. A Clevidence, and R. P Tracy Dietary fatty acids affect plasma markers of inflammation in healthy men fed controlled diets: a randomized crossover study Am. J. Clinical Nutrition, June 1, 2004; 79(6): 969 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D Zeltser, O Rogowski, S Berliner, T Mardi, D Justo, J Serov, M Rozenblat, D Avitzour, and I Shapira Sex differences in the expression of haemorheological determinants in individuals with atherothrombotic risk factors and in apparently healthy people Heart, March 1, 2004; 90(3): 277 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kang, K. Chu, and J.-K. Roh POEMS Syndrome, Fibrinogen, and Ischemic Stroke: A Critical Point of View--Reply Arch Neurol, January 1, 2004; 61(1): 155 - 156. [Full Text] [PDF]
|
|
|
|
|
|
E. Lutgens, R.-J. van Suylen, B. C. Faber, M. J. Gijbels, P. M. Eurlings, A.-P. Bijnens, K. B. Cleutjens, S. Heeneman, and M. J.A.P. Daemen Atherosclerotic Plaque Rupture: Local or Systemic Process? Arterioscler. Thromb. Vasc. Biol., December 1, 2003; 23(12): 2123 - 2130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. von Kanel and J. E. Dimsdale Hemostatic Alterations in Patients With Obstructive Sleep Apnea and the Implications for Cardiovascular Disease Chest, November 1, 2003; 124(5): 1956 - 1967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kamath and G.Y.H. Lip Fibrinogen: biochemistry, epidemiology and determinants QJM, October 1, 2003; 96(10): 711 - 729. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Palmieri, R. P. Tracy, M. J. Roman, J. E. Liu, L. G. Best, J. N. Bella, D. C. Robbins, B. V. Howard, and R. B. Devereux Relation of Left Ventricular Hypertrophy to Inflammation and Albuminuria in Adults With Type 2 Diabetes: The Strong Heart Study Diabetes Care, October 1, 2003; 26(10): 2764 - 2769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Bojesen, K. Juul, P. Schnohr, A. Tybjaerg-Hansen, and B.o. G. Nordestgaard Platelet glycoprotein IIb/IIIa PlA2/PlA2 homozygosity associated with risk of ischemic cardiovascular disease and myocardial infarction in young men: The Copenhagen City Heart Study J. Am. Coll. Cardiol., August 20, 2003; 42(4): 661 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Hackam and S. S. Anand Emerging Risk Factors for Atherosclerotic Vascular Disease: A Critical Review of the Evidence JAMA, August 20, 2003; 290(7): 932 - 940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.J. Malkin, P.J. Pugh, T.H. Jones, and K.S. Channer Testosterone for secondary prevention in men with ischaemic heart disease? QJM, July 1, 2003; 96(7): 521 - 529. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kain, J. M. Blaxill, A. J. Catto, P. J. Grant, and A. M. Carter Increased Fibrinogen Levels among South Asians versus Whites in the United Kingdom Are Not Explained by Common Polymorphisms Am. J. Epidemiol., July 15, 2002; 156(2): 174 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G.C. Spencer, D. Gurney, A. D. Blann, D. G. Beevers, and G. Y.H. Lip Von Willebrand Factor, Soluble P-Selectin, and Target Organ Damage in Hypertension: A Substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Hypertension, July 1, 2002; 40(1): 61 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Acevedo, G. L. Pearce, K. Kottke-Marchant, and D. L. Sprecher Elevated Fibrinogen and Homocysteine Levels Enhance the Risk of Mortality in Patients From a High-Risk Preventive Cardiology Clinic Arterioscler. Thromb. Vasc. Biol., June 1, 2002; 22(6): 1042 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P R J Ames, A Margarita, J D. Alves, C Tommasino, L Iannaccone, and V Brancaccio Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies Lupus, April 1, 2002; 11(4): 208 - 214. [Abstract] [PDF]
|
|
|
|
|
|
R Marchioli, F Avanzini, F Barzi, C Chieffo, A Di Castelnuovo, M.G Franzosi, E Geraci, A.P Maggioni, R.M Marfisi, N Mininni, et al. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations; GISSI-Prevenzione mortality risk chart Eur. Heart J., November 2, 2001; 22(22): 2085 - 2103. [Abstract] [PDF]
|
|
|
|
|
|
L. Iacoviello, M. Vischetti, F. Zito, and M. Benedetta Donati Genes Encoding Fibrinogen and Cardiovascular Risk Hypertension, November 1, 2001; 38(5): 1199 - 1203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Milionis, E. Rizos, and D. P. Mikhailidis Smoking Diminishes the Beneficial Effect of Statins: Observations from the Landmark Trials Angiology, September 1, 2001; 52(9): 575 - 587. [Abstract] [PDF]
|
|
|
|
|
|
K. Yano, J. S. Grove, R. Chen, B. L. Rodriguez, J. D. Curb, and R. P. Tracy Plasma Fibrinogen as a Predictor of Total and Cause-Specific Mortality in Elderly Japanese-American Men Arterioscler. Thromb. Vasc. Biol., June 1, 2001; 21(6): 1065 - 1070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Williams and P. F. Bray Genetics of Arterial Prothrombotic Risk States Experimental Biology and Medicine, May 1, 2001; 226(5): 409 - 419. [Abstract] [Full Text]
|
|
|
|
|
|
S. C. Clarke, P. M. Schofield, A. A. Grace, J. C. Metcalfe, and H. L. Kirschenlohr Tamoxifen Effects on Endothelial Function and Cardiovascular Risk Factors in Men With Advanced Atherosclerosis Circulation, March 20, 2001; 103(11): 1497 - 1502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. F. Bielak, G. G. Klee, P. F. Sheedy II, S. T. Turner, R. S. Schwartz, and P. A. Peyser Association of Fibrinogen With Quantity of Coronary Artery Calcification Measured by Electron Beam Computed Tomography Arterioscler. Thromb. Vasc. Biol., September 1, 2000; 20(9): 2167 - 2171. [Abstract] [Full Text] [PDF]
|
|